Latest News about Psychedelic/Assisted Therapies
Recent news which mentions Psychedelic/Assisted Therapies
Orange Photonics: New High-Tech Testing For Psychedelic Products
October 20, 2023
From Benzinga
Small Pharma's Q2 2024 Financial Highlights Ahead Of Cybin Merger For Global DMT Business
October 20, 2023
From Benzinga
From Benzinga
From Benzinga
EXCLUSIVE: Reason For Hope On Veteran Group Efforts, Comments To FDA & 2023 Expectations
October 18, 2023
From Benzinga
Lucy Scientific's Fiscal Year: Operating Expenses Rise As Accumulated Deficit Hits Over $44M
October 17, 2023
Tickers
LSDI
From Benzinga
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
October 16, 2023
From Benzinga
U.K.'s Prof. David Nutt Ranked World's Top Psychopharmacologist: More On His Contributions & Advocacy
October 15, 2023
Tickers
AWKNF
From Benzinga
Dem Presidential Candidate Calls For Universal Healthcare, Including Psychedelics Therapy
October 13, 2023
From Benzinga
Cybin And Small Pharma Shareholders Green Light Acquisition Resolution: Results & Expected Dates
October 13, 2023
From Benzinga
Pioneering Hope: Inside The Veteran's Organization Advancing Psychedelics Reform Policy
October 12, 2023
From Benzinga
EXCLUSIVE: Understanding Real Estate For Psychedelic Treatments Boosted By Geospatial Mapping
October 07, 2023
From Benzinga
EXCLUSIVE: The Need To Enhance Psychedelic Therapy Infrastructure, Data-Driven Solutions
October 06, 2023
From Benzinga
Maine's Portland Leads Drug Policy Reform, Decriminalizing Psychedelic Plants And Fungi
October 04, 2023
From Benzinga
Decoding Insurance Reimbursement For Psychedelic-Assisted Therapy With BrainFutures Guide
October 04, 2023
From Benzinga
Cybin Completes Dosing In Phase 2 Study Of CYB003 For Major Depressive Disorder Treatment
October 03, 2023
Tickers
CYBN
From Benzinga
From Benzinga
Insider's Look At Psychedelics Industry On Risk Management, Gray Market & Cannabis Industry
October 03, 2023
From Benzinga
GH Research's Psychedelic Drug Candidate For Depression Meets FDA: Clinical Program On Hold
October 02, 2023
Tickers
GHRS
From Benzinga
Gov Newsom Green Lights Medical Psychedelics If Rescheduled And New Marijuana Testing Rules
October 02, 2023
From Benzinga
Psychedelic Therapy Providers: Risk Management Perspective From A Cannabis Insurance Specialist
October 02, 2023
From Benzinga
Argentina's Nacho Bottinelli On Psychedelics In Latin America: 'Brazil Opened A Giant Portal To Me'
October 02, 2023
From Benzinga
Psyched: DMT & SSRIs For Depression, MDMA Training, Negative Responses To Psychedelics & More
October 02, 2023
From Benzinga
Psychedelics Reform Update: Massachusetts, Pennsylvania, Maine, California, Michigan, Minnesota, Indiana
September 30, 2023
From Benzinga
Cybin And Fluence Partner To Support EMBARK Training For Phase 3 CYB003 Trial For Depression
September 26, 2023
Tickers
CYBN
From Benzinga
Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results
September 26, 2023
From Benzinga
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
More ways to get to us
Facebook
Twitter
YouTubeContact the Lethbridge Herald
504 - 7th Street South
Lethbridge, AB T1J 3Z7
[P] (403) 328-4411
[F] (403)328-4536
Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433
© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.